Skip to main content
Clinical Trials/EUCTR2010-021777-37-DE
EUCTR2010-021777-37-DE
Active, not recruiting
Phase 1

A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month - Ranibizumab short- and long-term effects on retinal function in wAMD

niversitätsklinikum Schleswig-Holstein (UK-SH)0 sites20 target enrollmentAugust 9, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Retinal function in patients with wet age-related macular degeneration
Sponsor
niversitätsklinikum Schleswig-Holstein (UK-SH)
Enrollment
20
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2010
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversitätsklinikum Schleswig-Holstein (UK-SH)

Eligibility Criteria

Inclusion Criteria

  • 1\.wet age\-related macular degeneration (AMD)
  • 2\.an available follow\-up of 12 months
  • 3\. written informed consent
  • 4\. visual acuity of 0\.1 or better
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\.history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)
  • 2\.clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months
  • 3\. ventricular tachyarrythmias requiring ongoing treatment
  • 4\.History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation
  • 5\.Clinically significant impaired renal or hepatic function
  • 6\. Stroke within 12 month before trial entry.
  • 7\.Known serious allergies to the fluorescein dye use in angiography
  • 8\.Known contraindications to the components of Lucentis® formulation.
  • Ocular concomitant conditions/ diseases
  • 1\.Active intraocular inflammation (grade trace or above) in either eye

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months - Ranibizumab short- and long-term effects on retinal function in wAMDRetinal function in patients with wet age-related macular degenerationMedDRA version: 14.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-002202-70-DEniversitätsklinikum Schleswig-Holstein (UK-SH)
Not yet recruiting
Not Applicable
A single-centre study to check the visual performance and reduction in farsightedness in children with use of DIMSHYP spectacle lensesHealth Condition 1: H533- Other and unspecified disorders ofbinocular vision
CTRI/2024/08/072260Dr. Agarwal’s Eye Hospital Limited
Recruiting
Not Applicable
Applying a high frequency stimulator intended for shoulder pain patients
KCT0002545Chonbuk National University Hospital38
Active, not recruiting
Phase 1
A study of the antibiotic teicoplanin in adult patients with leukaemia, lymphoma or myeloma.
EUCTR2013-004535-72-IETallaght Hospital, Dublin 24, Ireland
Recruiting
Not Applicable
Safety and Efficacy evaluation of NANOTEX BONE graft along with fibula flap in reconstruction of segmental mandibular defect - A Pilot Clinical TrialHealth Condition 1: C00-D49- Neoplasms
CTRI/2022/07/044291Amrita Vishwa Vidyapeetham Amrita Institute of Medical Sciences